SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
2020; Cold Spring Harbor Laboratory; Linguagem: Inglês
10.1101/2020.05.19.20107482
AutoresDianna L. Ng, Gregory M. Goldgof, Brian R. Shy, Andrew G. Levine, Joanna Balcerek, Sagar P. Bapat, John Prostko, Mary A. Rodgers, Kelly E. Coller, Sandy Pearce, Sergej Franz, Li Du, Mars Stone, Satish K. Pillai, Alicia Sotomayor-González, Venice Servellita, Claudia Sanchez San Martin, Andrea Granados, Dustin R. Glasner, Lucy M. Han, Kent Truong, Naomi Akagi, David N. Nguyen, Neil M. Neumann, Daniel Qazi, Elaine Hsu, Wei Gu, Yale A. Santos, Brian Custer, Valerie Green, Phillip Williamson, Nancy K. Hills, Chuanyi M. Lu, Jeffrey D. Whitman, Susan L. Stramer, Candace Wang, Kevin Reyes, Jill Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Ching-Ying Oon, Steve Miller, Theodore W. Kurtz, John Hackett, Graham Simmons, Michael P. Busch, Charles Y. Chiu,
Tópico(s)SARS-CoV-2 detection and testing
ResumoABSTRACT We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and in vitro neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.
Referência(s)